In 201 patients with HCC and macrovascular invasion stable or responding on atezolizumab-bevacizumab, resection lengthened median time to treatment failure vs maintenance (20·4 vs 11·8 months; HR 0·60); grade 3–4 treatment-related events 39% vs 21%, 2 treatment-related deaths.
RCTn = 201
Sun et al. Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial